Evidence map›Paper›PMID 32323751›Full record

ArticleInternational journal of molecular medicine2020

Sulforaphane reduces intracellular survival of Staphylococcus aureus in macrophages through inhibition of JNK and p38 MAPK‑induced inflammation.

Therese B Deramaudt, Malika Ali, Stephane Vinit, Marcel Bonay

Open access · hybridAbstract read
In one paragraph

Article in International journal of molecular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 46 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Therese B DeramaudtDepartment of Neuromuscular Handicap: Biotherapies and Therapeutic Innovations, National Institute of Health and Medical Research, University of Versailles‑Saint‑Quentin‑en‑Yvelines, 78180 Montigny‑le‑Bretonneux, France.
Malika AliDepartment of Neuromuscular Handicap: Biotherapies and Therapeutic Innovations, National Institute of Health and Medical Research, University of Versailles‑Saint‑Quentin‑en‑Yvelines, 78180 Montigny‑le‑Bretonneux, France.
Stephane VinitDepartment of Neuromuscular Handicap: Biotherapies and Therapeutic Innovations, National Institute of Health and Medical Research, University of Versailles‑Saint‑Quentin‑en‑Yvelines, 78180 Montigny‑le‑Bretonneux, France.
Marcel BonayDepartment of Neuromuscular Handicap: Biotherapies and Therapeutic Innovations, National Institute of Health and Medical Research, University of Versailles‑Saint‑Quentin‑en‑Yvelines, 78180 Montigny‑le‑Bretonneux, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Macrophages are active contributors to the innate immune defense system. As macrophage activation is clearly affected by the surrounding microenvironment, the present study investigated the effect of sulforaphane (SFN) on the bactericidal activity of macrophages and the underlying molecular mechanisms involved in this process. Human THP‑1‑derived macrophages, primary human peripheral blood mononuclear cell‑derived macrophages, and primary mouse bone marrow derived‑macrophages (BMDMs) pretreated with SFN or DMSO were utilized in a model of Staphylococcus aureus infection. The results suggested that SFN pretreatment of macrophages effectively repressed the intracellular survival of S. aureus through modulation of p38/JNK signaling and decreased S. aureus‑induced caspases‑3/7‑dependent cell apoptosis, potentially through downregulation of microRNA (miR)‑142‑5p and miR‑146a‑5p. As SFN is a well‑known activator of nuclear factor erythroid 2‑related factor 2 (Nrf2), Nrf2‑/‑ BMDMs were used to demonstrate that the SFN‑mediated inhibitory effect was independent of Nrf2. Nevertheless, an increase in intracellular bacterial survival in Nrf2‑deficient macrophages was observed. In addition, SFN pretreatment suppressed S. aureus‑induced transcriptional expression of genes coding for the proinflammatory cytokines interleukin (IL)‑1β, IL‑6, and tumor necrosis factor‑α (TNF‑α), as well as for the M1 markers C‑C motif chemokine receptor 7, IL‑23 and inducible nitric oxide synthase (iNOS). Western blot analysis indicated that S. aureus challenge activated p38 mitogen‑activated protein kinase (MAPK) (p38) and c‑Jun N‑terminal kinase (JNK) MAPK signaling pathways, while SFN pretreatment prevented p38 and JNK phosphorylation. Pretreatment with 2 specific inhibitors of p38 and JNK, SB203580 and SP600125, respectively, resulted in a decrease in S. aureus‑induced proinflammatory gene expression levels compared with those observed in the SFN‑pretreated macrophages. Furthermore, THP‑1‑derived macrophages pretreated with SB203580 or SP600125 prior to bacterial infection exhibited a significant inhibition in intracellular S. aureus survival. In conclusion, we hypothesize that concomitant targeting of the p38/JNK‑inflammatory response and the S. aureus‑induced apoptosis with SFN may be a promising therapeutic approach in S. aureus infection.

Indexed as

AnimalsAnti-Bacterial AgentsApoptosisGene Expression RegulationHumansInflammationIsothiocyanatesMacrophagesMAP Kinase Kinase 4MAP Kinase Signaling SystemMice, Inbred C57BLMice, KnockoutNF-E2-Related Factor 2Reactive Oxygen SpeciesStaphylococcal InfectionsStaphylococcus aureusAnti-Bacterial AgentsIsothiocyanatesMAP Kinase Kinase 4Nfe2l2 protein, mouseNF-E2-Related Factor 2Reactive Oxygen SpeciessulforaphaneSulfoxides

Identifiers

PMID32323751
PMCPMC7169961
OpenAlexW3014178412

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.